Differences Between Infectious Disease Events in First Liver Transplant Versus Retransplantation in the Swiss Transplant Cohort Study.
Journal
Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
ISSN: 1527-6473
Titre abrégé: Liver Transpl
Pays: United States
ID NLM: 100909185
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
09
03
2021
received:
11
09
2020
accepted:
29
03
2021
pubmed:
11
4
2021
medline:
15
9
2021
entrez:
10
4
2021
Statut:
ppublish
Résumé
Retransplantation after graft failure is increasingly performed, and inferior graft survival, patient survival, and quality of life has been reported. The role of infectious disease (ID) events in this less favorable outcome is unknown. We analyzed ID events after first liver transplantation (FLTpx) and retransplantation (reLTpx) in the Swiss Transplant Cohort Study. Clinical factors were compared after FLTpx and reLTpx, and survival analysis was applied to compare the time to ID events after FLTpx and after reLTpx, adjusted for age, sex, Model for End-Stage Liver Disease score, donor type, liver transplant type (whole versus split liver), and duration of transplant surgery. In total, 60 patients were included (65.0% male, median age of 56 years). Overall, 343 ID events were observed: 204 (59.5%) after the FLTpx and 139 (40.5%) after reLTpx. Bacterial infections were most frequent (193/343, 56.3%), followed by viral (43/343, 12.5%) and fungal (28/343, 8.2%) infections, with less infections by Candida spp. but more by Aspergillus spp. after reLTpx (P = 0.01). The most frequent infection site was bloodstream infection (86, 21.3%), followed by liver and biliary tract (83, 20.5%) and intraabdominal (63, 15.6%) infections. After reLTpx, more respiratory tract and surgical site infections were observed (P < 0.001). The time to first infection was shorter after FLTpx (adjusted hazard ratio [HR], 0.5; 95%-confidence interval [CI], 0.3-1.0; P = 0.04). Reduced hazards for ID events after reLTpx were also observed when modelling recurrent events (adjusted HR, 0.5; CI, 0.3-0.8; P = 0.003). The number of infections was comparable after FLTpx and reLTpx; however, differences regarding infection sites and fungal species were observed. Hazards were reduced for infection after reLTpx.
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1283-1290Informations de copyright
Copyright © 2021 by the American Association for the Study of Liver Diseases.
Références
Kawut SM, Lederer DJ, Keshavjee S, Wilt JS, Daly T, D'Ovidio F, et al. Outcomes after lung retransplantation in the modern era. Am J Respir Crit Care Med 2008;1:114-120.
Magee JC, Barr ML, Basadonna GP, Johnson MR, Mahadevan S, McBride MA, et al. Repeat organ transplantation in the United States, 1996-2005. Am J Transplant 2007;7(Pt 2):1424-1433.
Broschewitz J, Wiltberger G, Krezdorn N, Krenzien F, Förster J, Atanasov G, et al. Primary liver transplantation and liver retransplantation: comparison of health-related quality of life and mental status-a cross-sectional study. Health Qual Life Outcomes 2017;15. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5521060/. Accessed April 30, 2018.
Rao PS, Ojo A. Organ retransplantation in the United States: trends and implications. Clin Transpl 2008;1:57-67.
Marudanayagam R, Shanmugam V, Sandhu B, Gunson BK, Mirza DF, Mayer D, et al. Liver retransplantation in adults: a single-centre, 25-year experience. HPB 2010;12:217-224.
de Castro Rodrigues Ferreira F, Cristelli MP, Paula MI, Proença H, Felipe CR, Tedesco-Silva H, et al. Infectious complications as the leading cause of death after kidney transplantation: analysis of more than 10,000 transplants from a single center. J Nephrol 2017;30:601-606.
Leong G, Wilson J, Charlett A. Duration of operation as a risk factor for surgical site infection: comparison of English and US data. J Hosp Infect 2006;63:255-262.
Koller MT, van Delden C, Müller NJ, Baumann P, Lovis C, Marti H-P, et al. Design and methodology of the Swiss Transplant Cohort Study (STCS): a comprehensive prospective nationwide long-term follow-up cohort. Eur J Epidemiol 2013;28:347-355.
van Delden C, Stampf S, Hirsch HH, Manuel O, Meylan P, Cusini A, et al. Burden and timeline of infectious diseases in the first year after solid organ transplantation in the Swiss Transplant Cohort Study. Clin Infect Dis 2020;71:e159-e169.
De Pauw B, Walsh T, Donnelly J, Stevens D, Edwards J, Calandra T, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008;46:1813-1821.
Amorim LDAF, Cai J. Modelling recurrent events: a tutorial for analysis in epidemiology. Int J Epidemiol 2015;44:324-333.
Therneau TM. A Package for Survival Analysis in R. https://CRAN.R-project.org/package=survival. Published 2020. Accessed April 8, 2020.
Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York: Springer-Verlag; 2000. Statistics for Biology and Health. https://www.springer.com/de/book/9780387987842. Accessed April 8, 2020.
Martí J, De la Serna S, Crespo G, Forns X, Ferrer J, Fondevila C, et al. Graft and viral outcomes in retransplantation for hepatitis C virus recurrence and HCV primary liver transplantation: a case-control study. Clin Transplant 2014;28:821-828.
Pfitzmann R, Benscheidt B, Langrehr JM, Schumacher G, Neuhaus R, Neuhaus P. Trends and experiences in liver retransplantation over 15 years. Liver Transpl 2007;13:248-257.
Cook CH, Zhang Y, McGuinness BJ, Lahm MC, Sedmak DD, Ferguson RM. Intra-abdominal bacterial infection reactivates latent pulmonary cytomegalovirus in immunocompetent mice. J Infect Dis 2002;185:1395-1400.
Chiche L, Forel J-M, Roch A, Guervilly C, Pauly V, Allardet-Servent J, et al. Active cytomegalovirus infection is common in mechanically ventilated medical intensive care unit patients. Crit Care Med 2009;37:1850-1857.
Reese TA, Wakeman BS, Choi HS, Hufford MM, Huang SC, Zhang X, et al. Helminth infection reactivates latent γ-herpesvirus via cytokine competition at a viral promoter. Science 2014;345:573-577.
Yong MK, Slavin MA, Kontoyiannis DP. Invasive fungal disease and cytomegalovirus infection: is there an association? Curr Opin Infect Dis 2018;31:481-489.
George MJ, Snydman DR, Werner BG, Griffith J, Falagas ME, Dougherty NN, Rubin RH. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997;103:106-113.
Hosseini-Moghaddam SM, Shokoohi M, Singh G, Dufresne SF, Boucher A, Jevnikar A, et al. A multicenter case-control study of the effect of acute rejection and cytomegalovirus infection on pneumocystis pneumonia in solid organ transplant recipients. Clin Infect Dis 2019;68:1320-1326.